ArticleOral oncology2025
Sentinel lymph node biopsy in early-stage oral squamous cell carcinoma: clinical outcomes and optimal lymph node removal thresholds.
Article in Oral oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Fluorescence Guidance Reduces Operative Time for Sentinel Lymph Node Biopsy in the Head and Neck.The Laryngoscope · 2026Article
- Sentinel lymph node biopsy in early-stage oral squamous cell carcinoma: reassessing its role in contemporary practice.Translational cancer research · 2026Article
- Can we now save the neck of OSCC T1-T2 patients? A narrative review of whether experimental techniques are on the way to clinical application.Exploration of targeted anti-tumor therapy · 2026Review
- Sentinel lymph node biopsy in early oral cancer: interpreting high significance in low-event cohorts.Translational cancer research · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSentinel lymph node biopsy (SLNB) is an effective method for managing clinically node-negative (cN0) early-stage oral squamous cell carcinoma (OSCC). This study examines lymphatic drainage patterns and clinical outcomes in pT1/T2 OSCC patients undergoing SLNB while establishing optimal thresholds for SLN identification and lymph node removal.
methodsClinicopathological data were analyzed to assess associations between SLN localization and tumor characteristics. Logistic regression identified risk factors for contralateral SLN involvement. Receiver operating characteristic curves determined optimal thresholds for SLN identification and lymph node removal. Survival analysis was conducted using Kaplan-Meier curves and log-rank tests.
resultsMost SLNs were ipsilateral (83.33 %), with fewer contralateral (8.33 %) or bilateral (8.33 %) cases. The most common SLN sites were Levels 1b and 2a (70.83 %), with Level 2a being the most frequent (39.58 %). Metastases were found in 8.33 % of patients, requiring neck dissection. During follow-up, 6.25 % experienced regional recurrence. Identifying ≥2 SLNs and removing >4 lymph nodes significantly improved recurrence-free survival (p < 0.05).
conclusionSLNB effectively maps lymphatic drainage in small OSCC tumors, detecting atypical pathways and metastases. Identifying at least two SLNs and removing more than four lymph nodes improves recurrence-free survival, highlighting the importance of thorough lymph node removal to optimize patient outcomes and reduce recurrence risk.
Indexed as
Identifiers
40812256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.